Professional in Biotech Finance brings top management and international
experience to BT PHARMA &mdash forerunner in Therapeutic VaccinesToulouse, France — Monday September 17, 2007. BT PHARMA S.A., forerunner in the development of therapeutic vaccines for treatment of neoplasia and cancer caused by the Human Papillomavirus (HPV), announced today that Martin Koch, engineer and INSEAD MBA, has been elected to the position of Vice-President Finance and Administration.
Before joining BT PHARMA, Martin Koch had an international career in financial and operational management positions at Eli Lilly Company, Cap Gemini / Ernst & Young, Elan Pharmaceuticals, Zeneus Pharma and Cephalon Pharmaceuticals. In particular, Mr Koch was instrumental in the transaction whereby a large part of Elan’s continental European activities were spun off to Zeneus Pharma.
"We are very pleased to welcome Martin Koch who brings over 15 years of pharmaceutical industry experience to our management team", explained Benedikt Timmerman, Chief Executive Officer of BT PHARMA. "We are entering in an accelerated growth phase and the recruitment of Martin fits well in our objective to reinforce our management with executives of top management level. Martin’s experience will be of great value for BT PHARMA as we start identifying strategic partners to finance our clinical trials Phase I and II."
About BT PHARMA S.A.
BT PHARMA is a privately held biopharmaceutical company spun out of the Institut Pasteur in 2002 and registered in Toulouse, France (home of Airbus Industries). The company develops immuno-therapeutics for cervical neoplasia and cancer. BT PHARMA’s key technology is a protein-based delivery system (the Adenylate Cyclase vector) that allows inducing tailor-made and targeted T cell immune responses in the patient. BT PHARMA exploits this technology to develop innovative therapeutic vaccines in-house and in partnership with biotech and pharmaceutical companies.
The young company’s most advanced product, ProCervix®, will enter phase I / II clinical trials in 2008. This bivalent therapeutic vaccine targets cervical neoplasia and cancer provoked by the human Papillomavirus (HPV). ProCervix® aims to replace ablative surgery or conisation in millions of women already infected by HPV16 or HPV18 and at risk for invasive cervical cancer.
Further information: http://www.btpharma.com
Source: BT Pharma
